Skip to main content
SpringerLink
Log in

Safety by Design

  • Published:
Drug Safety Aims and scope Submit manuscript

Summary

Safety by design for any kind of drug requires it to act selectively on the cells which mediate the desired effect, and affect other cellular functions as little as possible. To illustrate this, the treatment of bronchial asthma was much improved during the past 20 years by the development of inhalation treatment based on drugs such as salbutamol (albuterol), a selective β2-adrenoceptor stimulant, and beclomethasone dipropionate, a topical anti-inflammatory steroid, from their parent physiological mediators epinephrine (adrenaline) and hydrocortisone (cortisol). Their development and that of H1- and H2-antagonists from histamine are described. From these and other sources the general conditions for safe, selective drug action and the range of drug effects that may be attained by modifying physiological mediators are deduced. This involves the identification and definition of type 1 and type 2 agonism. This analysis led to the discovery of salmaterol (salmeterol), a new uniquely long acting β2-adrenergic bronchodilator, by modification of salbutamol. The development, by modification of serotonin (5-hydroxytryptamine), of ondansetron, a new antiemetic for use in cancer chemotherapy, and sumatriptan, a new type of drug for treating migraine, are also described. All these new drugs are more efficacious and safer than their predecessors.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Ahlquist RP. A study of the adrenotropic receptors. American Journal of Physiology 153: 586–600, 1948

    PubMed  CAS  Google Scholar 

  • Black JW, Duncan WAM, Durant GJ, Ganellin CR, Parsons MR. Definition and antagonism of histamine H2-receptors. Nature 236: 385–390, 1972

    Article  PubMed  CAS  Google Scholar 

  • Black JW, Stephenson JS. Pharmacology of a new adrenergic beta-receptor-blocking compound (Nethalide). Lancet 2: 311–314, 1962

    Article  PubMed  CAS  Google Scholar 

  • Bradley PB, Engel G, Feniuk W, Fozard JR, Humphrey PPA, et al. Proposals for the classification and nomenclature of functional receptors for 5-hydroxytryptamine. Neuropharmacology 25: 563–576, 1986

    Article  PubMed  CAS  Google Scholar 

  • Brittain RT, Dean CM, Jack D. Sympathomimetic bronchodilator drugs. Pharmacology and Therapeutics Bulletin 2: 423–462, 1976

    CAS  Google Scholar 

  • Brittain RT, Farmer JB, Jack D, Martin LE, Simpson WT. Alpha-[(t-butylamino) methyl]-4-hydroxy-m-xylene-alpha 1, alpha 3-diol; AH3365. A selective beta-adrenergic stimulant. Nature 219: 862–863, 1968

    Article  PubMed  CAS  Google Scholar 

  • Brittain RT, Jack D. Histamine H2-antagonists — past, present and future. Journal of Clinical Gastroenterology 5 (Suppl. 1): 71–79, 1983

    Article  PubMed  Google Scholar 

  • Brittain RT, Jack D, Sumner MJ. Further studies on the long duration of action of salmeterol, a new selective beta2-stimulant bronchodilator. Journal of Pharmacy and Pharmacology 40 (Suppl.): 93P, 1988

    Article  Google Scholar 

  • Costall B, Jones BJ, Kelly ME, Naylor RJ, Onàivi ES, et al. The potential of ondansetron to inhibit the behavioural consequences of withdrawing from chronic treatment with drugs of abuse. Pharmacology, Biochemistry and Behaviour, in press

  • Doenicke A, Brand B, Perrin VL. Possible benefit of GR43175, a novel 5HT-like receptor agonist for the acute treatment of severe migraine. Lancet 1: 1309–1311, 1988

    Article  PubMed  CAS  Google Scholar 

  • Feniuk W, Humphrey PPA, Perren MJ. The selective carotid arterial vasoconstrictor action of GR43175 in anaesthetised dogs. British Journal of Pharmacology 96: 83–90, 1989

    Article  PubMed  CAS  Google Scholar 

  • Gibson DG, Coltart DJ. Haemodynamic effects of intravenous salbutamol in patients with mitral valve disease — comparison with isoprenaline and atropine. Post-graduate Medical Journal 46 (Suppl.): 40–44, 1971

    Google Scholar 

  • Higgins GA, Kilpatrick GJ, Bunce KT, Jones BJ, Tyers MB. 5HT3-antagonists injected into the area postrema inhibit cisplatin-induced emesis in the ferret. British Journal of Pharmacology 97: 247–255, 1989

    Article  PubMed  CAS  Google Scholar 

  • Humphrey PPA, Feniuk W, Perren MJ, Oxford AW, Brittain RT. Sumatriptan succinate. Drugs of the Future 14: 35–39, 1989

    Google Scholar 

  • Jack D. Rational approaches to drug discovery. In Shanks RG (Ed.) Advanced medicine: topics in therapeutics 3, pp. 135–147, Pitman Medical, London, 1977

    Google Scholar 

  • Jack D. The challenge of drug discovery. Drug Design and Delivery 4: 167–186, 1989

    PubMed  CAS  Google Scholar 

  • Kilpatrick GJ, Jones BJ, Tyers MB. Identification and distribution of 5HT3-receptors in rat brain using radioligand binding. Nature 330: 746–748, 1987

    Article  PubMed  CAS  Google Scholar 

  • Kimball RW, Friedman MD, Vallejo E. Effect of serotonin in migraine patients. Neurology 10: 107–111, 1960

    Article  PubMed  CAS  Google Scholar 

  • Lance JW. Mechanism and management of headache, 2nd ed., Butterworth Publishers, London, 1973

    Google Scholar 

  • Lands AM, Arnold A, McAuliff JP, Luduena FP, Brown TG. Differentiation of receptor systems activated by sympathomimetic amines. Nature 214: 597–598, 1967a

    Article  PubMed  CAS  Google Scholar 

  • Lands AM, Luduena FP, Buzzo HJ. Differentiation of receptors responsive to isoproterenol. Life Sciences 8: 2241–2249, 1967b

    Article  Google Scholar 

  • Marty M. Ondansetron in the prophylaxis of cisplatin-induced emesis. Ondansetron Symposium (Glaxo), Queen Elizabeth II Conference Centre, London, June 29–30, pp. 49–53, 1989

    Google Scholar 

  • Mongar JL, Schild HO. Inhibition of the anaphylactic reaction. Journal of Physiology (London) 135: 301–319, 1957

    CAS  Google Scholar 

  • Neer EJ, Clapham DE. Roles of G-protein subunits in transmembrane signalling. Nature 333: 129–134, 1988

    Article  PubMed  CAS  Google Scholar 

  • Priestman TJ, Priestman SG. Studies with ondansetron in the management of radiation-induced emesis. Ondansetron Symposium (Glaxo), Queen Elizabeth II Conference Centre, London, June 29–30, pp. 34–37, 1989

    Google Scholar 

  • Richards DM, Brodgen RN, Heel RC, Speight TM, Avery GS. Astemizole. A review of its pharmacodynamic properties and therapeutic efficacy. Drugs 28: 31–61, 1984

    Article  Google Scholar 

  • Schmoll HJ. The role of ondansetron in the treatment of emesis induced by non-cisplatin-containing chemotherapy regimens. Ondansetron Symposium (Glaxo), Queen Elizabeth II Conference Centre, London, June 29–30, pp. 39–47, 1989

    Google Scholar 

  • Sharma BK, Walt RP, Pounder RE, Gomes MDA, Wood EC, Logan LH. Optimal dose of oral omeprazole for maximal 24 hour decrease of intragastric acidity. Gut 25: 957–964, 1984

    Article  PubMed  CAS  Google Scholar 

  • Sorkin EM, Heel RC. Terfenadine. A review of its pharmacodynamic properties and therapeutic efficacy. Drugs 29: 34–56, 1985

    CAS  Google Scholar 

  • Stables R, Andrews PLR, Baily HE, Costall B, Gunning SJ, et al. Antiemetic properties of the 5HT3-receptor antagonist, GR 38032F. Cancer Treatment Reviews 14: 333–336, 1987

    Article  PubMed  CAS  Google Scholar 

  • Starke K. Alpha-sympathomimetic inhibition of adrenergic and cholinergic transmission in the rabbit heart. Naunyn-Schmie-deberg’s Archives of Pharmacology 274: 18–45, 1972

    Article  CAS  Google Scholar 

  • Stephenson RP. A modification of receptor therapy. British Journal of Pharmacology 11: 379–393, 1956

    CAS  Google Scholar 

  • Tyers MB. The pharmacological and anti-emetic properties of ondansetron. Ondansetron Symposium (Glaxo), Queen Elizabeth II Conference Centre, London, June 29–30, pp. 18–23, 1989

    Google Scholar 

  • Ullman A, Svedmyr N. Salmeterol, a new long acting inhaled beta2-adrenoceptor agonist: comparison with salbutamol in adult asthmatic patients. Thorax 43: 674–678, 1988

    Article  PubMed  CAS  Google Scholar 

  • Wormsley KG. Risks of therapeutic achlorhydria. Scandinavian Journal of Gastroenterology 23 (Suppl. 153): 35–51, 1988

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Formerly of Glaxo Holdings plc, 6 The Slype, Gustard Wood, Wheathampstead, Hertfordshire AL4 8RY, London, United Kingdom

    David Jack

Authors
  1. David Jack
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jack, D. Safety by Design. Drug-Safety 5 (Suppl 1), 4–23 (1990). https://doi.org/10.2165/00002018-199000051-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-199000051-00004

Keywords

Search

Navigation